Medication-Assisted Treatment for Opioid Use Disorder

Medication-assisted treatment (MAT), also called medications for opioid use disorder (MOUD), is the use of approved medications to treat opioid use disorder by acting on the same opioid receptors that the drug targets. The three medication classes are the full agonist methadone, the partial agonist buprenorphine, and the antagonist naltrexone, used together with psychosocial support.

Definition

Medication-assisted treatment for opioid use disorder is the use of opioid agonist, partial-agonist, or antagonist medications, combined with psychosocial support, to stabilize patients, suppress withdrawal and craving, and reduce illicit opioid use.

Scope

This topic covers the pharmacological rationale for the three MOUD classes, the evidence that opioid agonist therapy keeps people in treatment and reduces illicit opioid use, and the place of these medications within a chronic-disease model of opioid use disorder. It is a reference entry and does not provide dosing or prescribing instructions.

Core questions

• How do agonist, partial-agonist, and antagonist medications differ in their action at the opioid receptor?
• What outcomes does opioid agonist therapy improve compared with no replacement therapy?
• Why is retention in treatment a central outcome for opioid use disorder?
• How does the chronic-disease framing justify long-term maintenance treatment?

Key concepts

• Opioid use disorder
• Opioid agonist therapy
• Methadone (full agonist)
• Buprenorphine (partial agonist)
• Naltrexone (antagonist)
• Maintenance versus detoxification
• Treatment retention

Mechanisms

Opioid medications act at the mu-opioid receptor. Methadone is a long-acting full agonist that occupies the receptor steadily, preventing withdrawal and blunting the euphoria of additional opioids without the peaks and troughs of short-acting drugs. Buprenorphine is a high-affinity partial agonist with a ceiling effect, relieving withdrawal and craving while carrying a lower overdose risk and displacing other opioids from the receptor. Naltrexone is a competitive antagonist that blocks the receptor entirely, so that taking an opioid produces no reinforcing effect. Mattick and colleagues showed in systematic review that methadone maintenance, by stabilizing the receptor system, retains patients in care and reduces heroin use relative to no opioid replacement.

Clinical relevance

Opioid agonist therapy is among the most strongly evidence-based treatments in addiction medicine and is associated with reduced illicit opioid use and improved treatment retention; understanding its mechanism supports critical reading of the field. This entry is educational and descriptive, and any medication choice, initiation, or dosing is a clinical decision governed by current guidelines, not by this reference.

Epidemiology

Opioid use disorder is a major contributor to drug-related morbidity and mortality, and the opioid overdose crisis has driven expansion of MOUD access. Despite strong evidence, a large share of people with opioid use disorder do not receive any of the approved medications.

Evidence & guidelines

Cochrane systematic reviews support agonist maintenance for retention and reduction of illicit opioid use, and major professional and public-health guidelines recommend methadone, buprenorphine, and extended-release naltrexone as first-line options. DSM-5 provides the diagnostic framework for opioid use disorder; specific recommendations should be drawn from current guidelines rather than this entry.

History

Methadone maintenance was introduced for opioid dependence in the 1960s and became the foundation of agonist treatment. Naltrexone offered an antagonist alternative, and buprenorphine, approved for office-based treatment in many countries in the early 2000s, broadened access by allowing treatment outside specialized clinics. The reframing of opioid use disorder as a chronic brain disorder supported the shift from short detoxification toward sustained maintenance.

Debates

Agonist maintenance versus antagonist or abstinence-based approaches

Agonist therapies (methadone, buprenorphine) have the strongest evidence for retention and reduced illicit use, while antagonist (naltrexone) and abstinence-oriented strategies face challenges with adherence and induction; the balance among approaches for a given patient remains debated.

Key figures

• Richard Mattick
• Marc Schuckit
• Nora Volkow

Seminal works

• mattick-2009
• schuckit-2016

Frequently asked questions

Is medication-assisted treatment just replacing one addiction with another?

No. Agonist medications such as methadone and buprenorphine are taken on a stable schedule under clinical supervision; they relieve withdrawal and craving without the cycle of intoxication and harm that characterizes a substance use disorder, and the evidence shows they improve retention in care and reduce illicit opioid use.

What is the difference between buprenorphine and naltrexone?

Buprenorphine is a partial opioid agonist that eases withdrawal and craving, whereas naltrexone is an opioid antagonist that blocks the receptor entirely so opioids produce no effect; they represent opposite pharmacological strategies.